1. OP0018 Pregnancy Outcomes with Trimesters of Maternal Exposure to Certolizumab Pegol: Prospective and Retrospective Reports from Safety Surveillance. (9th June 2015) Authors: Clowse, M.E.; Förger, F.; Cush, J.; Wolf, D.; Golembesky, A.; Shaughnessy, L.; De Cuyper, D.; Mahadevan, U. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0067 Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance. (10th June 2014) Authors: Clowse, M.E.B.; Wolf, D.C.; Förger, F.; Cush, J.J.; Golembesky, A.; Shaughnessy, L.; De Cuyper, D.; Luijtens, K.; Abbas, S.; Mahadevan, U. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Role of observational studies in supporting extrapolation of efficacy data from adults to children with epilepsy — A systematic review of the literature using lacosamide as an example. (July 2019) Authors: Arzimanoglou, A.; Kalilani, L.; Anamoo, M.A.; Cooney, M.; Golembesky, A.; Taeter, C.; Bozorg, A.; Tofighy, A.; Wheless, J. Journal: European journal of paediatric neurology Issue: Volume 23:Number 4(2019:Jul.) Page Start: 589 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study. (January 2019) Authors: Hochmair, M.; Cufer, T.; Morabito, A.; Hao, D.; Ta Yang, C.; Soo, R.; Yang, J.; Gucalp, R.; Halmos, B.; Wang, L.; Golembesky, A.; Märten, A.; O'Byrne, K. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study. (January 2019) Authors: Hochmair, M.; Cufer, T.; Morabito, A.; Hao, D.; Yang, C.; Soo, R.; Yang, J.C.; Rasim Gucalp, R.; Halmos, B.; Wang, L.; Golembesky, A.; Märten, A.; O'Byrne, K. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗